Skip to main content

Published locations for EHA: Venetoclax-rituxumab combo highly active in relapsed/refractory CLL

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. EHA: Venetoclax-rituxumab combo highly active in relapsed/refractory CLL

User login

  • Reset your password
  • /content/eha-venetoclax-rituxumab-combo-highly-active-relapsed/refractory-cll
  • /hematologynews/article/100465/cll/eha-venetoclax-rituxumab-combo-highly-active-relapsed/refractory
  • /oncologypractice/article/100465/cll/eha-venetoclax-rituxumab-combo-highly-active-relapsed/refractory
  • /hematology-oncology/article/100465/cll/eha-venetoclax-rituxumab-combo-highly-active-relapsed
  • /b-cell-lymphoma-icymi/article/100465/cll/eha-venetoclax-rituxumab-combo-highly-active-relapsed